Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
105.78
-1.95 (-1.81%)
At close: Mar 9, 2026, 4:00 PM EDT
105.78
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Glaukos Revenue
In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth. Glaukos had revenue of $143.12M in the quarter ending December 31, 2025, with 35.66% growth.
Revenue (ttm)
$507.44M
Revenue Growth
+32.33%
P/S Ratio
11.78
Revenue / Employee
$463,841
Employees
1,094
Market Cap
6.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Globus Medical | 2.94B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Integer Holdings | 1.85B |
| Masimo | 1.53B |
| Penumbra | 1.40B |
| LivaNova | 1.39B |
GKOS News
- 19 days ago - These Analysts Boost Their Forecasts On Glaukos Following Q4 Results - Benzinga
- 19 days ago - Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards - Seeking Alpha
- 5 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 5 weeks ago - Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire
- 6 weeks ago - Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 - Business Wire
- 7 weeks ago - Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha